Shares of Monopar Therapeutics Inc. (MNPR), a clinical-stage radiopharmaceutical company, are currently up over 450% at $25, following an agreement with Alexion, AstraZeneca Rare Disease for ALXN-1840, a late-stage Wilson disease drug candidate.
Alexion, AstraZeneca Rare Disease is a research group within AstraZeneca (AZN) focused on rare diseases. It was created in 2021 after AstraZeneca acquired Alexion Pharmaceuticals Inc. for $39 billion or $175 per share.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.